News | News By Subject | News by Disease News By Date | Search News

Allergies (misc) News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
BioPharm Executive: Ok, So It's Hillary     10/28/2016
5 Myths About Mylan (MYL)'s EpiPen Scandal     9/9/2016
Backlash Leads Mylan (MYL) to Launch First Generic EpiPen at Half the Price     8/29/2016
Facing Public Backlash and Pressure from Clinton, Mylan (MYL) Caves and Lowers Price of EpiPen     8/26/2016
Outrage Ensues After Mylan (MYL) Raises EpiPen Price by 400%     8/24/2016
Merck & Co. (MRK) to Terminate Allergy Agreement With ALK-Abello A/S     7/27/2016
Allergy Therapeutics Phase II Fails to Find Hay Fever Therapy Dose Range     6/27/2016
Circassia (CIR.L) Stock Crashes as Allergy Drug Flunks Crucial Phase III Study     6/20/2016
Ocular Therapeutix (OCUL)'s Pink Eye Treatment Dextenza Flunks Phase III Test     6/6/2016
Rubius Therapeutics Springs Out of Flagship VentureLabs to Take on PKU with Red Cell Therapeutics     12/9/2015
Sanofi (SNY) May Suffer a $109 Million Hit from Injector Recall     10/29/2015
Astellas (ALPMY), Immunomic Forge $300 Million+ LAMP-vax Pact     10/9/2015
DBV Tech Nabs FDA Breakthrough Status for Peanut Allergy Patch     4/13/2015
Adamis (ADMP) Plummets More Than 30% After FDA Rejects Its Allergy Shot Application     4/1/2015
GlaxoSmithKline (GSK) Down Slightly After Johnson & Johnson (JNJ) Allergy Ad Settlement     3/31/2015

News from Around the Web
Mylan (MYL) CEO Hopes EpiPen Furor Leads To "Price Transparency"     12/5/2016
Mylan (MYL) CEO Bresch Admits "Full Responsibility" For EpiPen Price Hikes     12/2/2016
Are Food Allergies On The Rise? Experts Say They Don't Know     12/1/2016
Meet The Woman Who Is Allergic To Everything - Including Her Husband     11/21/2016
A Pill May Soon Replace Mylan (MYL)'s Costly EpiPen     11/21/2016
PRECISION Results Open The Door For OTC Celebrex     11/15/2016
There's A Patch That Could Fix Your Peanut Allergy Problem, DBV Tech Reveals     11/2/2016
The First Peanut Allergy Therapy Might Soon Hit The Shelves, DBV Tech Reveals     10/26/2016
Health Officials Should Reject Latest Gambit By EpiPen Maker To Feed At The Public Trough     10/18/2016
Mylan (MYL) Stock Rises -- Is There A Light At The End Of The Tunnel?     10/11/2016
Mylan (MYL) CEO to be Grilled by Congress Over EpiPen Pricing     9/15/2016
Biotech CEOs: Please Don't Let EpiPen Threaten Innovation     9/13/2016
The EpiPen Debacle Coupled With Theranos And Turing: Is This Industry Broken?     9/9/2016
Kids With Exposure To Antibiotics Linked To Allergies Later In Life, Utrecht University Study     9/6/2016
New Wearable Devices Aim To Detect Allergens In Food And In The Air, Allergy Amulet Reveals     8/15/2016

Press Releases
Kaleo Release: Pharma Announces U.S. Availability And Pricing To Patients Of AUVI-Q (Epinephrine Injection, USP) Auto-Injector, For Life-Threatening Allergic Reactions     1/19/2017
Astellas (ALPMY) Announces FDA Fast Track Designation For ASP0892, DNA Vaccine For Mitigation Of Severe Hypersensitivity Reactions Due To Peanut Allergy     12/20/2016
Aralez Announces Commercial Launch Of BLEXTEN In Canada     12/19/2016
AnaptysBio Announces Clearance Of U.S. IND And U.K. CTA For ANB020     12/13/2016
Aimmune (AIMT) Completes Global Enrollment Of Phase III PALISADE Trial Of AR101 For The Treatment Of Peanut Allergy     11/28/2016
Bayer (BAY) Release: 20+ Years Of Safety Data, Clinical Trials & Real-World Use Confirm Positive Benefit/Risk Profile Of ALEVE     11/14/2016
DBV Tech Completes Enrollment Of Phase II Study Of Viaskin Milk For The Treatment Of Milk Allergic Patients     11/8/2016
Second Genome Partners With King's College London To Evaluate The Influence Of The Microbiome In Landmark EAT Study     10/11/2016
Mylan (MYL) Forks Over $465 Million to Settle EpiPen Overpricing Case     10/10/2016
Mylan (MYL)'s Generic EpiPen Reportedly Ready By End Of Year     10/5/2016
Mylan (MYL) Hopes To Extend Epipen Shelf Life Extra 6 Months     9/28/2016
Immune Design Corporation (IMDZ) Announces Advancement Of First GLAAS-Based Allergy Program Into Clinical Development     9/28/2016
ASIT Biotech Announces The Initiation Of A Phase IIa Clinical Study Of Its Second Product Candidate Hdm-ASIT+TM For House Dust Mite Rhinitis     9/22/2016
Intercept Pharma (ICPT) Files New Drug Submission To Health Canada For Marketing Approval Of Obeticholic Acid For The Treatment Of Patients With Primary Biliary Cholangitis     9/19/2016
Allakos Begins Clinical Trials Of AK002 In Patients With Systemic Mastocytosis     9/15/2016